ERBB2 and breast carcinoma: A Phase I trial was designed to determine the MTD of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive breast cancer, with a planned follow-on Phase II component with pathological complete response as the primary endpoint.